Assessment of activity and resistance mechanisms to cefepime in combination with the novel β-lactamase inhibitors zidebactam, taniborbactam and enmetazobactam against a multicenter collection of carbapenemase-producing Enterobacterales
Author – Vázquez-Ucha JC, Lasarte-Monterrubio C, Guijarro-Sánchez P, Oviaño M, Álvarez-Fraga L, Alonso-García I, Arca-Suárez J, Bou G, Beceiro A; GEMARA-SEIMC/REIPI Enterobacterales Study Group
Journal Name – Antimicrob Agents Chemother.
Citation – 2022 Feb 15;66(2):e0167621
In Vitro Activity of Cefiderocol, Cefepime-Zidebactam, and β-Lactam Combinations Versus Other Antibiotic Classes Against Various Sequence Types of Clinically Isolated Carbapenemase-Producing Klebsiella pneumoniae
Author – hamnoi P, Jumroon N, Khamphakul J, Chaihongsa N, Santanirand P
Journal Name – Microb Drug Resist.
Citation – 2023 Sep;29(9):416-422
Case Commentary: Successful Use of Cefepime/Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia
Author – Egge SL, Lewis JS 2nd, Hakki M
Journal Name – Antimicrob Agents Chemother.
Citation – 2023 Aug 17;67(8):e0066323
Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern
Author – Le Terrier C, Nordmann P, Buchs C, Di DYW, Rossolini GM, Stephan R, Castanheira M, Poirel L
Journal Name – J Antimicrob Chemother.
Citation – 2023 Sep 5;78(9):2382-2384
Enantiomeric Separation and Thermodynamic Investigation of (R)-N-Tert-Butoxy Carbonyl-Piperidine-3-Carboxylic Acid Hydrazide, a Key Starting Material of Zidebactam
Author – Rane VP, Ahirrao VK, More KB, Yeole RD
Journal Name – J Chromatogr Sci.
Citation – 2021 Apr 21; 59(5):452-457
In Vitro Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018
Author – Yang Y, Guo Y, Yin D, Zheng Y, Wu S, Zhu D, Hu F
Journal Name – Antimicrob Agents Chemother.
Citation – 2020 Dec 16;65(1):e01726-20
Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales
Author – Blanco-Martín T, López-Hernández I, Aracil B, González-Pinto L, Aja-Macaya P, Alonso-García I, Rodríguez-Pallares S, Sánchez-Peña L, Outeda-García M, Pérez-Vázquez M, Vázquez-Ucha JC, Beceiro A, Pascual Á, Bou G, López-Cerero L, Oteo-Iglesias J, Arca-Suárez J; GEMARA-SEIMC/CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT)
Journal Name – Antimicrob Agents Chemother.
Citation – 2024 Nov 6;68(11):e0092424
Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions
Author – Blanco-Martín T, Alonso-García I, González-Pinto L, Outeda-García M, Guijarro-Sánchez P, López-Hernández I, Pérez-Vázquez M, Aracil B, López-Cerero L, Fraile-Ribot P, Oliver A, Vázquez-Ucha JC, Beceiro A, Bou G, Arca-Suárez J; GEMARA/SEIMC-CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT)
Journal Name – Int J Antimicrob Agents
Citation – 2024 May;63(5):107150
Antibiotic Susceptibility of NDM-Producing Enterobacterales Collected in the United States in 2017 and 2018
Author – Lutgring JD, Balbuena R, Reese N, Gilbert SE, Ansari U, Bhatnagar A, Boyd S, Campbell D, Cochran J, Haynie J, Ilutsik J, Longo C, Swint S, Rasheed JK, Brown AC, Karlsson M
Journal Name – Antimicrob Agents Chemother.
Citation – 2020 Aug 20;64(9):e00499-20
In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations
Author – Palwe S, Bakthavatchalam YD, Khobragadea K, Kharat AS, Walia K, Veeraraghavan B
Journal Name – Antibiotics (Basel)
Citation – 2021 Oct 29;10(11):1318
In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales
Author – Dutkiewicz M, Jousset AB, de Swardt H, Rezzoug I, Bonnin RA, Dortet L, Emeraud C
Journal Name – J Antimicrob Chemother.
Citation – 2026 Jan 6;81(1):dkaf440
Decreased susceptibility to cefepime/zidebactam among carbapenemase-producing Escherichia coli from Stockholm, Sweden with alterations in PBP2
Author – Tellapragada C, Dunleavy C, Jonsson P, Giske CG
Journal Name – J Antimicrob Chemother.
Citation – 2025 Apr 2;80(4):1137-1140
In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases
Author – Le Terrier C, Nordmann P, Poirel L
Journal Name – J Antimicrob Chemother.
Citation – 2022 Dec 23;78(1):101-107
Multicenter surveillance of in vitro activities of cefepime-zidebactam, cefepime-enmetazobactam, omadacycline, eravacycline, and comparator antibiotics against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii complex causing bloodstream infection in Taiwan, 2020
Author – Jean SS, Ko WC, Lu MC, Lee WS, Hsueh PR; SMART Program
Journal Name – Expert Rev Anti Infect Ther.
Citation – 2022 Jun;20(6):941-953
In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020
Author – Liu PY, Ko WC, Lee WS, Lu PL, Chen YH, Cheng SH, Lu MC, Lin CY, Wu TS, Yen MY, Wang LS, Liu CP, Shao PL, Lee YL, Shi ZY, Chen YS, Wang FD, Tseng SH, Lin CN, Chen YH, Sheng WH, Lee CM, Tang HJ, Hsueh PR
Journal Name – J Microbiol Immunol Infect.
Citation – 2022 Oct;55(5):888-895
Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates. (ZID Tested at fixed 4 mg/L)
Author – Cedano J, Baez M, Pasteran F, Montaña SD, Ra G, Fua V, Corso A, Tolmasky ME, Bonomo RA, Ramírez MS
Journal Name – Front Cell Infect Microbiol.
Citation – 2022 Jul 8;12:918868
In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates
Author – Tascini C, Bianco G, Bonomo RA, Gaibani P
Journal Name – J Antimicrob Chemother.
Citation – 2026 Jan 19;81(2):dkaf467
Tackling the unyielding: testing two novel approaches against NDM-producing Enterobacterales and Pseudomonas aeruginosa isolates collected in India
Author – Bakthavatchalam YD, Behera B, Shah A, Mathur P, Ray R, Fomda BA, Walia K, Veeraraghavan B
Journal Name – Microbiol Spectr.
Citation – 2025 Jan 7;13(1):e0049724
In vitro activity of zidebactam/cefepime (WCK 5222), a β-lactam enhancer/β-lactam combination against carbapenem- and colistin-resistant Klebsiella pneumoniae isolates
Author – Bakthavatchalam YD, Shankar C, Jeyaraj C, Neeravi A, Mathur P, Nagvekar V, Nithiyanandam S, Walia K, Veeraraghavan B
Journal Name – Diagn Microbiol Infect Dis.
Citation – 2025 Jan;111(1):116561
Successful use of cefepime/zidebactam in deep-seated infections due to extensively drug-resistant Pseudomonas aeruginosa - a case series
Author – Shah P, Neeravi A, Karthik R, Mathew CM, Hephzibah J, Johnson HE, Veeraraghavan B, Manesh A
Journal Name – J Glob Antimicrob Resist
Citation – 2025 Sep;44:464-469
Cefepime-zidebactam therapy for extensively drug-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae infection as a bridge to liver transplantation
Author – Tsai S, Nigo M, Kang D, Baptista RP, Tamma PD, Jacobs E, Bergman Y, Victor DW, Connor AA, Saharia A, Ghobrial RM, Arias CA, Miller WR
Journal Name – JAC Antimicrob Resist.
Citation – 2025 Jul 17;7(4):dlaf129
Evaluation of imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam and cefepime-zidebactam activities on a wide collection of French clinical Enterobacterales isolates
Author – Petillon C, Ulutuipalelei M, Beyrouthy R, Proust S, Aissa N, Bret L, Brieu N, Carricajo A, Cattoir V, Dauwalder O, Degand N, Dortet L, Doucet-Populaire F, Dubois V, Grillon A, Guérin F, Lanotte P, Lemaitre N, Leyssene D, Neuwirth C, Patry I, Ploy MC, Podglajen I, Recule C, Rouis K, Réseau O, Robert J, Bonnet R, Robin F
Journal Name – Diagn Microbiol Infect Dis.
Citation – 2025 Nov;113(3):117011
In vitro activity of cefepime-zidebactam, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and other comparators against imipenem-non-susceptible Pseudomonas aeruginosa in Taiwan, 2022
Author – Lee YL, Tan MC, Chen PJ, Shiau YR, Wang HY, Lai JF, Huang IW, Yang YS, Kuo SC
Journal Name – Int J Antimicrob Agents
Citation – 2025 Sep;66(3):107550
Antimicrobial resistance among imipenem-non-susceptible Escherichia coli and Klebsiella pneumoniae isolates, with an emphasis on novel β-lactam/β-lactamase inhibitor combinations and tetracycline derivatives: The Taiwan surveillance of antimicrobial resistance program, 2020–2022
Author – Lee YL, Liu CE, Wang WY, Tan MC, Chen PJ, Shiau YR, Wang HY, Lai JF, Huang IW, Yang YS, Kuo SC
Journal Name – J Microbiol Immunol Infect.
Citation – 2025 Apr;58(2):219-225
Multidrug‑resistant Gram‑negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
Author – Le Terrier C, Freire S, Nordmann P, Poirel L
Journal Name – Eur J Clin Microbiol Infect Dis.
Citation – 2024 Feb;43(2):339-354
Investigational antibiotic cefepime/zidebactam as a therapeutic option for the treatment of an unyielding empyema in a paediatric patient caused by extensively drug-resistant Pseudomonas aeruginosa: a case report
Author – Vishnu Rao Polati, Santosh Gattu, Venkata Nagarjuna Maturu, P. Swati Prakasham & Maryam Maqsood
Journal Name – European Journal of Clinical Microbiology & Infectious Diseases
Citation – Volume 44, pages 1349–1355, (2025)
Difficult to treat Pseudomonas: successful salvage therapy with cefepime-zidebactam
Author – Anjely Sebastian, Shivdas Naik, Muralidhar Varma, N C Sreekumar, Joseph Thomas, Tanvi Rao, Birva J Shah, Nitin Gupta
Journal Name – Transactions of The Royal Society of Tropical Medicine and Hygiene
Citation – Volume 118, Issue 9, September 2024, Pages 632–634,
Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by New Delhi metallo-β-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime/zidebactam (WCK 5222)
Author – Rajeev Soman, Rasika Sirsat, Ayesha Sunavala, Neha Punatar, Jugal Mehta, Camilla Rodrigues & Balaji Veeraraghavan
Journal Name – European Journal of Clinical Microbiology & Infectious Diseases
Citation – Article published in Feb 2024
Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through β-lactam-enhancer-mechanism-based cefepime/zidebactam
Author – Andrea M. Hujer, Steven H. Marshall, Andrew R. Mack, Kristine M. Hujer, Yamuna Devi Bakthavatchalam, Kushal Umarkar, Snehal R. Palwe, Robert A. Bonomo
Journal Name – Antimicrobial Chemotherapy
Citation – Vol. 14, No .6, October 2023
In Vitro Activity of Cefiderocol, Cefepime-Zidebactam, and β-Lactam Combinations Versus Other Antibiotic Classes Against Various Sequence Types of Clinically Isolated Carbapenemase-Producing Klebsiella pneumoniae
Author – Phadungkiat Khamnoi, Noppadon Jumroon, Jakkrit Khamphakul, Narong Chaihongsa, and Pitak Santanirand
Journal Name – Microbial Drug Resistance
Citation – Vol. 29, No. 9, August 2023
Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report
Author – Dilip Dubey, Manish Roy, Tajamul H. Shah, Noor Bano, Vidushi Kulshrestha, Sandeep Mitra, Pushpender Sangwan, Madhulika Dubey, Ali Imran, Bhawna Jain, Aravind Velmurugan, Yamuna Devi Bakthavatchalam & Balaji Veeraraghavan
Journal Name – Annals of Clinical Microbiology and Antimicrobials
Citation – 22, Article number: 55 (July 2023)
In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates
Author – Christophe Le Terrier , Patrice Nordmann, Mustafa Sadek, Laurent Poirel
Journal Name – Journal of Antimicrobial Chemotherapy
Citation – 2023 May; 78(5): 1191–1194
Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia
Author – Praveen Kumar Tirlangi, Bala Saheb Wanve, Ramakanth Reddy Dubbudu, Boorgula Sushma Yadav, L. Siva Kumar, Anand Gupta, Racha Amarthya Sree, Hari Priya Reddy Challa, P. Naveen Reddy
Journal Name – Antimicrobial Agents and Chemotherapy
Citation – 2023 Aug; 67(8):e0050023
In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India
Author – Bakthavatchalam YD, Elangovan D, Jaganathan SV, Subburaju N, Shankar A, Manokaran Y, J S, Devi R, Baveja S, Devi S, S J, Bhattacharya S, S M R, Yesudhason B, Shetty V, Mutreja A, Manesh A, Varghese GM, Marwick CA, Parcell BJ, Gilbert IH, Veeraraghavan B
Journal Name – Microbiology spectrum
Citation – 2023 Feb 27;11(2):e0492522
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa
Author – Cristina Lasarte-Monterrubio, Pablo Arturo Fraile-Ribot, Juan Carlos Vázquez-Ucha, Gabriel Cabot, Paula Guijarro-Sánchez, Isaac Alonso-García, Soraya Rumbo-Feal, Fátima Galán-Sánchez, Alejandro Beceiro, Jorge Arca-Suárez, Antonio Oliver, Germán Bou
Journal Name – Journal of Antimicrobial Chemotherapy
Citation – 2022, AOP, dkac241
Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)
Author – Helio S Sader, Rodrigo E Mendes, Leonard R Duncan, Cecilia G Carvalhaes, Mariana Castanheria
Journal Name – Journal of Antimicrobial Chemotherapy
Citation –2022, 77(10),2642-2649
In Vitro Activity of New β-Lactam–β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019
Author – Yan Guo, Renru Han, Bo Jiang, Li Ding, Fengzhen Yang, Beijia Zheng, Yang Yang, Shi Wu, Dandan Yin, Demei Zhu, Fupin Hu
Journal Name – Microbiology Spectrum
Citation –2022, AOP, e0185422
Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-ResistantPseudomonas aeruginosaClinical Isolate
Author – Xiaolei Pan, Xinrui Zhao, Yuqin Song, Huan Ren, Zhenyang Tian, Qi’an Liang, Yongxin Jin, Fang Bai, Zhihui Cheng, Jie Feng, Weihui Wu
Journal Name – Microbiology Spectrum
Citation – 2022, 10(1), e02678-21
Assessment of activity and resistance mechanisms to cefepime in combination with the novel β-lactamase inhibitors zidebactam, taniborbactam and enmetazobactam against a multicenter collection of carbapenemase-producing Enterobacterales
Author – Juan Carlos Vázquez-Ucha, Cristina Lasarte-Monterrubio, Paula Guijarro-Sánchez , Marina Oviaño, Laura Álvarez-Fraga, Isaac Alonso-García, Jorge Arca-Suárez, German Bou Alejandro Beceiro
Journal Name – Antimicrobial Agents and Chemotherapy
Citation – AAC Accepted AAC.01676-21
Antimicrobial Activity of Aztreonam in Combination with Old and New -Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible ptions for the Treatment of Complicated Infections
Author – Gianluca Morroni, Raffaela Bressan, Simona Fioriti, Gloria D’Achille, Marina Mingoia, Oscar Cirioni, Stefano Di Bella, Aurora Piazza, Francesco Comandatore, Carola Mauri, oberta Migliavacca, Francesco Luzzaro, Luigi Principe, Cristina Lagatolla
Journal Name – Antibiotics
Citation –2021, 10(11), 1341
Activity of β-lactam plus β-lactam-enhancer combination cefepime/zidebactam against Klebsiella pneumoniae harbouring defective OmpK35/36 porins and arbapenemases
Author – Prashant Joshi, Rahul Shrivastava, Sachin Bhagwat, Mahesh Patel
Journal Name – Diagnostic Microbiology and Infectious Disease
Citation –2021, 101(2), 115481
In vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline, and other comparative agents against carbapenem-nonsusceptible Enterobacterales: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017–2020
Author – Yu-Lin Lee, Wen-Chien Ko, Wen-Sen Lee, Po-Liang Lu, Yen-Hsu Chen, Shu-Hsing Cheng, Min-Chi Lu, Chi-Ying Lin, Ting-Shu Wu, Muh-Yong Yen, Lih-Shinn Wang, Chang-Pan Liu, Pei-Lan Shao, Zhi-Yuan Shi, Yao-Shen Chen, Fu-Der Wang, Shu-Hui Tseng, Chao-Nan Lin, Yu-Hui Chen, Wang-Huei Sheng, Chun-Ming Lee, Hung-JenTang, Po-Ren Hsueh
Journal Name – International Journal of Antimicrobial Agents
Citation –2021, 58(3), 106377
Comment on: An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa
Author – Nicolau David, Bhagwat Sachin, Abdelraouf Kamilia
Journal Name – Journal of Antimicrobial Chemotherapy
Citation –2021, 76(12), 3326–3327
In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy
Author – Barceló Isabel; Cabot Gabriel; Palwe Snehal; Joshi Prashant; Takalkar Swapna; Periasamy Hariharan; Cortes-Lara Sara; Zamorano Laura; Sanchez-Diener Irina; Moya Bartolome; Bhagwat Sachin; Patel Mahesh; Oliver Antonio
Journal Name – Journal of Antimicrobial Chemotherapy
Citation – JAC-2021-dkab213
Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model
Author – Maxwell J Lasko, Kamilia Abdelraouf, David P Nicolau
Journal Name – Journal of Antimicrobial Chemotherapy
Citation – 2021, 76(9) 2310–2316
Activity of cefepime/zidebactam (WCK 5222) against ‘problem’ antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory
Author – Shazad Mushtaq, Paolo Garello, Anna Vickers, Neil Woodford, David M Livermore
Journal Name – Journal of Antimicrobial Chemotherapy
Citation – 2021, 76(6), 1511–1522
In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan
Author – Shu-Chen Kuo, Yung-Chih Wang, Mei-Chen Tan, Wei-Cheng Huang, Yih-Ru Shiau, Hui-Ying Wang, Jui-Fen Lai, I-Wen Huang and Tsai-Ling Lauderdale
Journal Name – Journal of Antimicrobial Chemotherapy
Citation – 2021 Jul 15;76(8):2071-2078
In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals
Author – Sachin S Bhagwat, Nicholas J Legakis, Tilemachos Skalidis, Anastassios loannidis, Christos Goumenopoulos, Prashant R Joshi, Rahul Shrivasta
Journal Name – Diagnostic Microbiology and Infectious Disease
Citation – 2021, 100(3), 115327
Structural characterization of diazabicyclooctane b-Lactam "Enhancers" in complex with penicillin-binding proteins PBP2 and PBP3 of Pseudomonas aeruginosa
Author – Rajavel Malligarjunan, Kumar Vijay, Nguyen Ha, Wyatt Jacob, Marshall Steven H, Papp-Wallace Krisztina M, Deshpande Prasad, Bhavsar Satish, Yeole Ravindra, Bhagwat Sachin, Mahesh Patel, Robert A Bonomo, Focco van den Akker
Journal Name – mBio
Citation – 2021, 12(1), e03058-20
In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems
Author – Karlowsky James A, Hackel Meredith A, Bouchillon Samuel K, Sahm Daniel F
Journal Name – Antimicrobial Agents and Chemotherapy
Citation – 2020, 64(12), e01432-20
Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3
Author – Sachin S Bhagwat, Periasamy Hariharan, Prashant R Joshi, Snehal R Palwe, Rahul Shrivastava, Mahesh V Patel
Journal Name – Journal of Antimicrobial Chemotherapy
Citation – 2020, 75(12), 3563-3567
Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa
Author – Bartolome Moya, Sachin Bhagwat, Gabriel Cabot, German Bou, Mahesh Patel, Antonio Oliver
Journal Name – Journal of Antimicrobial Chemotherapy
Citation – 2020, 75(6), 1474-1478
Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope
Author – Avery Lindsay M, Mullane Elias M, Nicolau David P
Journal Name – International Journal of Antimicrobial Agents
Citation – 2020, 55(2), 105863
Comparative evaluation of the in vitro activities of WCK 5222 (cefepime/zidebactam) and combination antibiotic therapies against carbapenem-resistant Pseudomonas aeruginosa
Author – Elias M. Mullane, Lindsay M. Avery, David P. Nicolau
Journal Name – Antimicrobial Agents and Chemotherapy
Citation – 2020, 64(3), e01669-19
Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model
Author – James M. Kidd, Kamilia Abdelraouf, David P. Nicolau
Journal Name – Journal of Antimicrobial Chemotherapy
Citation – 2020, 75(1), 149–155
WCK 5222 (Cefepime/Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-lactamase producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model
Author – Alexander J. Lepak, Miao Zhao, David R. Andes
Journal Name – Antimicrobial Agents and Chemotherapy
Citation – 2019, 63(12), 01648-19
Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York city medical centres
Author – Zeb Khan, Alejandro Iregui, David Landman, John Quale
Journal Name – Journal of Antimicrobial Chemotherapy
Citation – 2019, 74(10), 2938–2942
In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model
Author – Marguerite L. Monogue, Jennifer Tabor-Rennie, Kamilia Abdelraouf, David P. Nicolau
Journal Name – Antimicrobial Agents and Chemotherapy
Citation – 2019, 63(7), e00233-19
In vitro and in vivo activity of β-lactams in combination with novel β-lactam enhancers, zidebactam and WCK 5153, against multidrug-resistant metallo-β-lactamase producing Klebsiella pneumoniae
Author – Bartolome Moya, Isabel Maria Barceló, Gabriel Cabot, Gabriel Torrens, Snehal Palwe, Prashant Joshi, Kushal Umarkar, Swapna Takalkar, Hariharan Periasamy, Sachin Bhagwat, Mahesh V. Patel, Germán Bou, and Antonio Oliver
Journal Name – Antimicrobial Agents and Chemotherapy
Citation – 2019, 63(5), e00128-19
The Novel β-Lactam Enhancer Zidebactam Augments the In Vivo Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung Acinetobacter baumannii Infection Model
Author – Bhagwat S. S, Periasamy H, Takalkar S. S, Palwe S. R, Khande H. N, Patel M. V
Journal Name – Antimicrobial Agents and Chemotherapy
Citation – 2019, 63(4), e02146-18
Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens
Author – Thomson Kenneth S, Abdel Ghani Sameh, Snyder James W, Thomson Gina K, Abdel Ghani Sameh, Thomson Gina K
Journal Name – Antibiotics
Citation – 2019, 8(1), 32
Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment
Author – Richard A Preston, Grigor Mamikonyan, Stephane DeGraff, James Chiou, Christopher J Kemper, Allan Xu, Mushtaque Mastim, Ravindra Yeole, Rajesh Chavan, Anasuya Patel, H David Friedland, Ashima Bhatia
Journal Name – Antimicrobial Agents and Chemotherapy
Citation – 2019, 63(1), e01484-18
In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model. S.S.Almarzoky Abuhussain
Author – S.S.Almarzoky Abuhussain, Lindsay M. Avery, Kamilia Abdelraouf, David P. Nicolau
Journal Name – Antimicrobial Agents and Chemotherapy
Citation – 2019, 63(1), e01931-18
Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234
Author – Papp-Wallace Krisztina M, Nguyen Nhu Q, Jacobs Michael R, Bethel Christopher R, Barnes Melissa D, Kumar Vijay, Bajaksouzian, Saralee, Rudin Susan D, Rather Philip N, Bhavsar Satish
Journal Name – Journal of Medicinal Chemistry
Citation – 2018, 61(9), 4067-4086
Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects
Author – Keith A Rodvold, Mark H Gotfried, Rakesh Chugh, Mugdha Gupta, Anasuya Patel, Rajesh Chavan, Ravindra Yeole, H David Friedland, Ashima Bhatia
Journal Name – Antimicrobial Agents and Chemotherapy
Citation – 2018, 62(8), e00682-18
Simultaneous determination of zidebactam and cefepime in dog plasma by LC–MS/MS and its application to pre‐clinical pharmacokinetic study
Author – Kiran Patil, Harshad Tambe, Vineet Zope, Rajesh Chavan, Ravindra Yeole, Mahesh V. Patel
Journal Name – Biomedical Chromatography
Citation – 2018, 32(8), e4249
Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-ResistantAcinetobacter baumannii in the Neutropenic Murine Lung Infection Model
Author – Avery Lindsay M, Abdelraouf Kamilia, Nicolau David P, Nicolau David P
Journal Name – Antimicrobial Agents and Chemotherapy
Citation – 2018, 62 (11), e00948-18
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015
Author – Helio S. Sader, Mariana Castanheira, Michael Huband, Ronald N. Jones, Robert K. Flamm
Journal Name – Antimicrobial Agents and Chemotherapy
Citation – 2017, 61(5), e00072-17
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases
Author – Helio S Sader, Paul R Rhomberg, Robert K Flamm, Ronald N Jones, Mariana Castanheira
Journal Name – Journal of Antimicrobial Chemotherapy
Citation – 2017, 72(6), 1696-1703
Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates
Author – Bartolome Moya, Isabel M. Barcelo, Sachin Bhagwat, Mahesh V. Patel, German Bou, Krisztina M. Papp-Wallace, Robert A. Bonomo Antonio Oliver
Journal Name – Antimicrobial Agents and Chemotherapy
Citation – 2017, 61(11), e01238-17
In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria
Author – Livermore DM, Mushtaq S, Warner M, Vickers A, Woodford N,
Journal Name – Journal of Antimicrobial Chemotherapy
Citation – 2017, 72(5), 1373–1385
WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent “β-Lactam Enhancer” Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β- Lactamase-Producing High-Risk Clones
Author – Moya Bartolome, Barcelo Isabel M, Oliver Antonio, Bhagwat Sachin, Patel Mahesh, Bou German, Papp-Wallace Krisztina M, Bonomo Robert A, Papp-Wallace Krisztina M, Bonomo Robert A
Journal Name – Antimicrobial Agents and Chemotherapy
Citation – 2017, 61(6), e02529-16